Background: Nitric oxide is synthesized in endothelial cells by eNOS and acts as a pleiotropic regulator involved in carcinogenesis. Most gastric cancers develop from stomach epithelial cells therefore, NO may play a role in their development. Polymorphisms of eNOS have been shown to be associated with cancer susceptibility. In the present study, we investigated the association of the eNOS genotypes with gastric cancer risk in Guilan Population.

Materials and Methods: In this case-control study, we analyzed the Glu298Asp polymorphism of eNOS in 87 patients with gastric cancer and 90 healthy controls. The genotyping of eNOS polymorphism was performed using polymerase chain reaction–restriction fragment length polymorphism assays. All statistical analyses were conducted by the MedCalc statistical software.

Results: No association between the eNOS genotypes and gastric cancer risk was found. Among the 87 patients, 45 had Glu/Glu, 38 were Glu/Asp, and 4 were Asp/Asp. In the control group, 44 had Glu/Glu, 40 were Glu/Asp, and 6 were Asp/Asp. We found no significant differences in allele and genotype frequencies between control and patient specimens.

Conclusion: We found that there was no association between this polymorphism and gastric cancer risk. Results suggest that eNOS polymorphism may play a role in inhibition of gastric cancer. However, larger population-based studies are needed for clarifying the role of eNOS polymorphism in gastric cancer.